RESOURCES
AMMI Canada Media Publications
- Respiratory and medical microbiology & infectious disease societies encourage flu and COVID-19 vaccines as the pandemic persists
- Des sociétés de médecine respiratoire, de microbiologie médicale et d’infectiologie encouragent la vaccination contre la grippe et la COVID-19 alors que la pandémie se poursuit
AMMI Canada Media Publications
- Respiratory and medical microbiology & infectious disease societies encourage simple daily actions to prevent the spread of respiratory viral illnesses
- Des organismes de médecine respiratoire, de microbiologie médicale et d’infectiologie encouragent des gestes simples au quotidien pour prévenir la propagation d’infections virales respiratoires
Antimicrobial Stewardship and Resistance
Asymptomatic bacteriuria
Cannabis
- Le cannabis au Canada – Renseignez-vous sur les faits
- Cannabases
- Lignes directrices de réduction des risques liés à l’utilisation du cannabis au Canada
AFN National First Nations Cannabis Summit (March 28-29, 2019) (English | Français)
Canadian Antimicrobial Resistance Surveillance System (CARSS)
The CARSS report provides an integrated picture of antimicrobial resistance (AMR) and antimicrobial use (AMU) in Canada, prioritizing data acquired by the Public Health Agency of Canada (PHAC) and its partners. Web links to this year’s report will be circulated shortly.
This year’s report provides details on AMR in organisms of highest concern to Canadians, as well as information on AMU in human and animal populations. In summary:
- There are indications that the AMR landscape is worsening in humans.
- AMU continues to increase in humans, particularly in elderly Canadians.
- Despite overall declines, the quantities of antimicrobials sold for use in animals increased between 2017 and 2018.
The growing trend of AMR is a problem that no entity can solve on its own. We look forward to the continued and improved integration of AMR and AMU data from all PHAC partners, as we collaboratively work towards limiting the rise of AMR infections in Canada.
Chief Public Health Officer (CPHO)
The CPHO Health Professional Forum’s publications on Principles for Engaging with First Nations, Inuit and Métis and Common Definitions on Cultural Safety
Chief Public Health Officer of Canada spotlight report on Handle with Care: Preserving Antibiotics Now and Into the Future.
This report highlights the social and cultural drivers of the unnecessary prescribing and improper use of antibiotics in Canada and describes what Canadians, health care providers, and health system leaders can do to reduce inappropriate antibiotic use and conserve their effectiveness.
Influenza
- Highly Pathogenic Avian Influenza Outbreak in Canada
- 2021-2022 AMMI Canada guidance on the use of antiviral drugs for influenza in the COVID-19 pandemic setting in Canada
- AMMI Canada: Use of antiviral drugs for seasonal influenza: Foundation document for practitioners—Update 2019
- FLU(influenza): FluWatch surveillance
Lyme Disease
- AMMI Canada Position Statement on the Diagnosis and Treatment of People with Persistent Symptoms That Have Been Attributed to Lyme Disease
- Énoncé de position de l’AMMI Canada sur le diagnostic de la maladie de Lyme et le traitement des personnes ayant des symptômes persistants attribués à cette maladie
- The Facts about Lyme disease: What You Need To Know
- Les faits sur la maladie de Lyme : Ce qu’il faut savoir
Resources
- Canada.ca/Lymedisease
- Centre for Effective Practice’s Early Lyme Disease Management in Primary Care Tool
- Canada.ca/Maladiedelyme
- Prise en charge en soins primaires de la maladie de Lyme au stade précoce du Centre for Effective Practice
- Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis
NEW: The internet can be a valuable source of information; it can also be difficult sometimes to tell what information is backed up by good science. Here are some reliable sites that can help answer your questions:
- https://www.niaid.nih.gov/diseases-conditions/chronic-lyme-disease
- https://www.cdc.gov/lyme/faq/index.html
Federal Framework
- Lyme Disease in Canada – A Federal Framework (English French)
- AMMI Canada’s response to the Draft Federal Framework on Lyme Disease
Surveillance
Monkeypox
National Advisory Committee on Immunization (NACI)
NACI makes recommendations for the use of vaccines currently or newly approved for use in humans in Canada, including the identification of groups at risk for vaccine-preventable diseases for whom vaccination should be targeted. NACI knowledge syntheses, analyses and recommendations on vaccine use in Canada are published in literature reviews, statements and updates.
New statements are those which have been published within the past five years. Previous statements are those which are were published over five years ago and have been archived.
NACI recommendations are also published in vaccine-specific chapters of the Canadian Immunization Guide.
- Guidance on the Prioritization of Key Populations for COVID-19 Immunization
- Orientations sur la priorisation des populations principales pour l’immunisation contre la COVID-19
- NACI Recommendations on the Use of COVID-19 Vaccine
- CCNI Recommandations sur l’utilisation des vaccins contre la COIVD-19
- Recommendations on the Duration of the Post-vaccination Observation Period for Influenza Vaccination during the COVID-19 Pandemic
- Recommendation on the Use of Live Attenuated Influenza Vaccine (LAIV) in HIV-Infected Individuals
- NACI Research Priorities for COVID-19 Vaccines to Support Public Health Decisions
- Interim guidance on continuity of immunization programs during the COVID-19 pandemic
- Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2020–2021
Email updates are available through our mailing list. To subscribe to receive instant alerts when chapter updates and new NACI products are posted.
Novel Coronavirus
- NEW! Health Canada announces Coalition for Action for Health Workers
- NEW! Webinar: Routine childhood vaccination: How to address lapses during COVID-19 (Nov 24, 2022 12:00 PM ET)
- NEW! Health Canada authorizes second bivalent COVID-19 booster targeting the Omicron BA.4/5 variants
- NEW! Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022: Recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults
- NEW! Infographic: Examining how changes in alcohol and cannabis consumption varied by experiences of stigma during the COVID-19 pandemic in Canada
- NEW! Inequalities in the mental health of adults before and during the COVID-19 pandemic: data tool
- Post COVID-19 condition
- COVID-19 for health professionals: Post COVID-19 condition
- Reporting ocular adverse events following COVID‐19 vaccination: Communication to healthcare professionals
- COVID-19: Symptoms, treatment, what to do if you feel sick
- COVID-19 vaccines and treatments portal
- Statement from the Public Health Agency of Canada on Omicron Variant
- Statement from the Government of Canada on Omicron Variant
- Statement from the Honourable Jean-Yves Duclos, Minister of health on Omicron Variant
Coronanvirus disease (COVID-19): Outbreak Update and the COVID-19 Virtual Assistant – ca/coronavirus
Use ArriveCAN to provide mandatory travel information (described video)
Update on COVID-19 in Canada: Epidemiology and modelling (December 11, 2020)
Coronavirus disease (COVID-19): Vaccines
Pfizer-BioNTech COVID-19 vaccine: Health Canada recommendations for people with serious allergies
Authorization of Pfizer-BioNTech COVID-19 Vaccine with English-only Carton and Vial Labels
- Canada to receive early access to Moderna COVID-19 vaccine
- COVID-19 mRNA vaccines
- Vaccines and treatments for COVID-19: Progress
- Canada’s COVID-19 Immunization Plan: Saving Lives and Livelihoods
- Health Canada authorizes first COVID-19 vaccine
- COVID-19 immunization: Federal, provincial and territorial statement of common principles
- International Coalition of Medicines Regulatory Authorities statement on continuation of vaccine trials
- Vaccines and treatments for COVID-19: Vaccine rollout
- Coronavirus disease (COVID-19): Awareness resources
- READ MORE
PUBLICATIONS
AMMI Canada
- Highly Pathogenic Avian Influenza Outbreak in Canada
- Webinar: Monkeypox in Canada: What clinicians need to know
- Canadian Tuberculosis Standards - 8th Edition
- Canadian Tuberculosis (TB) Standards 8th Edition HIGHLIGHTS
- NEW - AMMI Canada urges political leaders and healthcare organizations across Canada to make COVID-19 vaccination a condition of employment for healthcare workers.
- NOUVEAU - L’AMMI Canada exhorte les chefs de file politiques et les organismes de santé du Canada à faire de la vaccination contre la COVID-19 une condition d’emploi pour les travailleurs de la santé.
- The Practice Point: Duration of Antibiotic Therapy for Common Infections
- Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis
- Use of antiviral drugs for seasonal influenza: Foundation document for practitioners - Update 2019
- Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection
- Choosing Wisely Canada—Top five list in medical microbiology: An official position statement of the Association of Medical Microbiology and Infectious Disease (AMMI) Canada
- The use of antiviral drugs for influenza: A foundation document for practitioners
- L'’utilisation de médicaments antiviraux contre l’influenza : Un document de base pour les praticiens
- AMMI Canada Position Statement on the Diagnosis and Treatment of People with Persistent Symptoms That Have Been Attributed to Lyme Disease
- Énoncé de position de l’AMMI Canada sur le diagnostic de la maladie de Lyme et le traitement des personnes ayant des symptômes persistants attribués à cette maladie
- AMMI Canada Position statement on the PHAC Federal Framework on Lyme Disease
- FMT Directory
AMMI Canada
- Highly Pathogenic Avian Influenza Outbreak in Canada
- Webinar: Monkeypox in Canada: What clinicians need to know
- Canadian Tuberculosis Standards - 8th Edition
- Canadian Tuberculosis (TB) Standards 8th Edition HIGHLIGHTS
- NEW - AMMI Canada urges political leaders and healthcare organizations across Canada to make COVID-19 vaccination a condition of employment for healthcare workers.
- NOUVEAU - L’AMMI Canada exhorte les chefs de file politiques et les organismes de santé du Canada à faire de la vaccination contre la COVID-19 une condition d’emploi pour les travailleurs de la santé.
- The Practice Point: Duration of Antibiotic Therapy for Common Infections
- Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis
- Use of antiviral drugs for seasonal influenza: Foundation document for practitioners - Update 2019
- Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection
- Choosing Wisely Canada—Top five list in medical microbiology: An official position statement of the Association of Medical Microbiology and Infectious Disease (AMMI) Canada
- The use of antiviral drugs for influenza: A foundation document for practitioners
- L'’utilisation de médicaments antiviraux contre l’influenza : Un document de base pour les praticiens
- AMMI Canada Position Statement on the Diagnosis and Treatment of People with Persistent Symptoms That Have Been Attributed to Lyme Disease
- Énoncé de position de l’AMMI Canada sur le diagnostic de la maladie de Lyme et le traitement des personnes ayant des symptômes persistants attribués à cette maladie
- AMMI Canada Position statement on the PHAC Federal Framework on Lyme Disease
- FMT Directory
Canadian Nosocomial Infection Surveillance Program (CNISP)
- Canadian Nosocomial Infection Surveillance Program
Antimicrobial Utilization (AMU) Protocol - Canadian Nosocomial Infection Surveillance Program
Hospital Antibiogram Protocol - Canadian Nosocomial Infection Surveillance Program
Surveillance for Candida auris - Canadian Nosocomial Infection Surveillance Program
Surveillance for Clostridioides difficile infection (CDI)
CDI Surveillance Protocol - Canadian Nosocomial Infection Surveillance Program
Surveillance for Central Line Associated Blood Stream Infections
(CLABSI) in Intensive Care Units (ICUs) CLABSI Surveillance Protocol - Canadian Nosocomial Infection Surveillance Program
Surveillance Protocol for Carbapenemase-Producing Organisms (CPO) in CNISP Hospitals - Canadian Nosocomial Infection Surveillance Program
Surveillance of Cerebrospinal Fluid (CSF) Shunt Associated Surgical Site Infections (SSIs) Surveillance Protocol - Canadian Nosocomial Infection Surveillance Program
Surveillance Protocol for the Enhanced Hospital Profile (EHP) - Canadian Nosocomial Infection Surveillance Program
Surveillance of Surgical Sites Infections (SSIs) Following Hip and Knee Arthroplasty - Canadian Nosocomial Infection Surveillance Program
2023 Surveillance Protocol for Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections in CNISP Hospitals - Canadian Nosocomial Infection Surveillance Program
Surveillance of Surgical Sites Infections Following Pediatric Cardiac Surgery
Pediatric Cardiac SSI Surveillance Protocol - Canadian Nosocomial Infection Surveillance Program
Surveillance Protocol for Vancomycin Resistant Enterococcus Bloodstream Infections in CNISP Hospitals - Canadian Nosocomial Infection Surveillance Program
Surveillance for viral respiratory infections among inpatients in CNISP hospitals
- Programme canadien de surveillance des infections nosocomiales
Protocole de surveillance 2023 des infections à Staphylococcus aureus résistant à la méthicilline et sensible à la méthicilline dans les hôpitaux du PCSIN - Programme canadien de surveillance des infections nosocomiales
Protocole d’hôpital sur l’antibiogramme - Programme canadien de surveillance des infections nosocomiales
Surveillance de Candida auris - Programme canadien de surveillance des infections nosocomiales
Surveillance des infections du sang à entérocoques résistants à la vancomycine
(ERV) dans les hôpitaux participant au PCSIN - Programme canadien de surveillance des infections nosocomiales
Surveillance des infections à Clostridioides difficile (ICD) - Programme canadien de surveillance des infections nosocomiales
Surveillance des infections des sites opératoires (ISO) après une opération cardiaque pédiatrique
Protocole de surveillance des ISO cardiaques pédiatriques - Programme canadien de surveillance des infections nosocomiales
Surveillance des infections du site opératoire (ISO) après une arthroplastie de la hanche ou du genou - Programme canadien de surveillance des infections nosocomiales
Surveillance des infections du site opératoire (ISO) des voies de dérivation du liquid céphalorachidien (LCR)
Protocole de surveillance - Programme canadien de surveillance des infections nosocomiales
Surveillance des infections du système sanguin associées aux cathéters centraux (ISSACC) dans les unités de soins intensifs (USI)
Protocole de surveillance des ISSACC - Programme canadien de surveillance des infections nosocomiales
Protocole de surveillance des organismes producteurs de carbapénémases (OPC) dans les hôpitaux du PCSIN - Programme canadien de surveillance des infections nosocomiales
Surveillance du profil détaillé des hôpitaux (PDH) - Programme canadien de surveillance des infections nosocomiales
Protocole d’utilisation des antimicrobiens (UAM) - Programme canadien de surveillance des infections nosocomiales
Surveillance des infections respiratoires virales chez les patients hospitalisés dans les hôpitaux du PCSIN
Canadian Nosocomial Infection Surveillance Program (CNISP)
- Canadian Nosocomial Infection Surveillance Program
Antimicrobial Utilization (AMU) Protocol - Canadian Nosocomial Infection Surveillance Program
Hospital Antibiogram Protocol - Canadian Nosocomial Infection Surveillance Program
Surveillance for Candida auris - Canadian Nosocomial Infection Surveillance Program
Surveillance for Clostridioides difficile infection (CDI)
CDI Surveillance Protocol - Canadian Nosocomial Infection Surveillance Program
Surveillance for Central Line Associated Blood Stream Infections
(CLABSI) in Intensive Care Units (ICUs) CLABSI Surveillance Protocol - Canadian Nosocomial Infection Surveillance Program
Surveillance Protocol for Carbapenemase-Producing Organisms (CPO) in CNISP Hospitals - Canadian Nosocomial Infection Surveillance Program
Surveillance of Cerebrospinal Fluid (CSF) Shunt Associated Surgical Site Infections (SSIs) Surveillance Protocol - Canadian Nosocomial Infection Surveillance Program
Surveillance Protocol for the Enhanced Hospital Profile (EHP) - Canadian Nosocomial Infection Surveillance Program
Surveillance of Surgical Sites Infections (SSIs) Following Hip and Knee Arthroplasty - Canadian Nosocomial Infection Surveillance Program
2023 Surveillance Protocol for Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections in CNISP Hospitals - Canadian Nosocomial Infection Surveillance Program
Surveillance of Surgical Sites Infections Following Pediatric Cardiac Surgery
Pediatric Cardiac SSI Surveillance Protocol - Canadian Nosocomial Infection Surveillance Program
Surveillance Protocol for Vancomycin Resistant Enterococcus Bloodstream Infections in CNISP Hospitals - Canadian Nosocomial Infection Surveillance Program
Surveillance for viral respiratory infections among inpatients in CNISP hospitals
- Programme canadien de surveillance des infections nosocomiales
Protocole de surveillance 2023 des infections à Staphylococcus aureus résistant à la méthicilline et sensible à la méthicilline dans les hôpitaux du PCSIN - Programme canadien de surveillance des infections nosocomiales
Protocole d’hôpital sur l’antibiogramme - Programme canadien de surveillance des infections nosocomiales
Surveillance de Candida auris - Programme canadien de surveillance des infections nosocomiales
Surveillance des infections du sang à entérocoques résistants à la vancomycine
(ERV) dans les hôpitaux participant au PCSIN - Programme canadien de surveillance des infections nosocomiales
Surveillance des infections à Clostridioides difficile (ICD) - Programme canadien de surveillance des infections nosocomiales
Surveillance des infections des sites opératoires (ISO) après une opération cardiaque pédiatrique
Protocole de surveillance des ISO cardiaques pédiatriques - Programme canadien de surveillance des infections nosocomiales
Surveillance des infections du site opératoire (ISO) après une arthroplastie de la hanche ou du genou - Programme canadien de surveillance des infections nosocomiales
Surveillance des infections du site opératoire (ISO) des voies de dérivation du liquid céphalorachidien (LCR)
Protocole de surveillance - Programme canadien de surveillance des infections nosocomiales
Surveillance des infections du système sanguin associées aux cathéters centraux (ISSACC) dans les unités de soins intensifs (USI)
Protocole de surveillance des ISSACC - Programme canadien de surveillance des infections nosocomiales
Protocole de surveillance des organismes producteurs de carbapénémases (OPC) dans les hôpitaux du PCSIN - Programme canadien de surveillance des infections nosocomiales
Surveillance du profil détaillé des hôpitaux (PDH) - Programme canadien de surveillance des infections nosocomiales
Protocole d’utilisation des antimicrobiens (UAM) - Programme canadien de surveillance des infections nosocomiales
Surveillance des infections respiratoires virales chez les patients hospitalisés dans les hôpitaux du PCSIN
Other Association
- Literature Review on Immunization in Pregnancy with Tetanus Toxoid, Reduced Diphtheria Toxoid and Reduced Acellular Pertussis (Tdap) Vaccine: Safety, Immunogenicity and Effectiveness
- Revue documentaire sur l’immunisation durant la grossesse par le vaccin combiné anti-Tétanos, et à dose réduite contre la diphtérie et la coqueluche acellulaire (dcaT) : Innocuité, immunogénicité et efficacité
- Update on Immunization in Pregnancy with Tetanus Toxoid, Reduced Diphtheria Toxoid and Reduced Acellular Pertussis (Tdap) Vaccine
- Mise à jour sur l'immunisation durant la grossesse avec le vaccin combiné anti-Tétanos, et à dose réduite contre la diphtérie et la coqueluche acellulaire (dcaT)
- PHAC - Canadian Guidelines on Sexually Transmitted Infections
- Canadian Public Health Laboratory Network Interim Laboratory Testing Guidance For The Detection Of Non-Tuberculous Mycobacteria (NTM) Infections In Post Operative Patients Exposed To Heater Cooler Units
- Directive provisoire du Réseau des laboratoires de santé publique du Canada sur les essais de laboratoire visant à détecter les infections postopératoires causées par des mycobactéries non tuberculeuses (MNT) chez les patients exposés à des échangeurs
- Canadian Tuberculosis Standards, 7th Edition 2014
Other Association
- Literature Review on Immunization in Pregnancy with Tetanus Toxoid, Reduced Diphtheria Toxoid and Reduced Acellular Pertussis (Tdap) Vaccine: Safety, Immunogenicity and Effectiveness
- Revue documentaire sur l’immunisation durant la grossesse par le vaccin combiné anti-Tétanos, et à dose réduite contre la diphtérie et la coqueluche acellulaire (dcaT) : Innocuité, immunogénicité et efficacité
- Update on Immunization in Pregnancy with Tetanus Toxoid, Reduced Diphtheria Toxoid and Reduced Acellular Pertussis (Tdap) Vaccine
- Mise à jour sur l'immunisation durant la grossesse avec le vaccin combiné anti-Tétanos, et à dose réduite contre la diphtérie et la coqueluche acellulaire (dcaT)
- PHAC - Canadian Guidelines on Sexually Transmitted Infections
- Canadian Public Health Laboratory Network Interim Laboratory Testing Guidance For The Detection Of Non-Tuberculous Mycobacteria (NTM) Infections In Post Operative Patients Exposed To Heater Cooler Units
- Directive provisoire du Réseau des laboratoires de santé publique du Canada sur les essais de laboratoire visant à détecter les infections postopératoires causées par des mycobactéries non tuberculeuses (MNT) chez les patients exposés à des échangeurs
- Canadian Tuberculosis Standards, 7th Edition 2014